The Path to Affordable Therapeutics in Rare Disease – Tackling Congenital Disorder of Glycosylation in the PMM2 gene.

Authors: Alexandra Narin, Hannah Huston, and Chris Hopkins

By definition, there are not a lot of patients for any given Rare Disease. A disease is only considered rare (or “orphan”) if it affects fewer than 200,000 people (NIH). Often, a rare genetic condition caused by a malfunction of a gene is even more infrequent. Maybe only a small handful of people on the planet will have genetic lesions in a given gene. Despite this, rare disease as a group is actually quite common. There are over 7,000 genes in everyone’s genome that can harbor a gene variation which leads to a disease. One way to conceptualize the variants in a rare disease is to imagine an inverted image of a galaxy, where black dot clusters of Rare variants have different levels of phenotypic severity (Figure 1). The variant clusters in the outer fringes are near normal activity, but in the center is the black null of lethality.

CREDIT: Adapted from the European Space Agency

Although a pair of individuals with similar variations in a given gene is not often found, the likelihood that any two individuals will have a defective variation in any one of the 7,000 genes is much higher. The result is that about 1 in 15 persons are afflicted with a rare disease condition. So, in aggregate, it turns out that rare diseases are a highly common health care issue that suppresses quality of life for a large proportion of the planet’s population.

The challenge of today’s personalized medicine is to develop therapeutic approaches that can treat these rare disease populations in a cost effective way. In the traditional therapeutic development path, the cost to bring a chemical entity through the challenges of toxicity and efficiency and have it reach the market, has cost billions of dollars. This sizable sum of money can be challenging to justify when only a dozen or so individuals will stand to benefit from such a high cost. As a society, we must get inventive and find more affordable approaches to bring rare disease therapeutics to market. Answering this call to action are small biotech companies, such as Perlara.

Perlara, located in the San Francisco Bay Area, was founded in February 2014 by Ethan Perlstein. The company is “on a mission to accelerate the discovery of cures for rare genetic diseases and uncover underlying mechanisms that enable the development of treatments that work across a range of diseases and individuals” (Perlara Website). Through their PerlQuests™, Perlara partners with families, researchers, and patients to find treatments for these otherwise forgotten, yet very real, rare diseases. One such PerlQuest, focusing on PMM2 (Phosphomannomutase 2 deficiency), holds a special place in the heart of Dr. Sangeetha Iyer, the Director of Preclinical Development at Perlara.

Dr. lyer (currently a senior PM at Pfizer) has a background in neurodegenerative disorders and rare genetic diseases. She received her Ph.D. in molecular pharmacology from the University of Pittsburgh and then went on to do her postdoc research at the University of Texas, Austin. Sangeetha has worked with a plethora of models, starting her career with mouse models, and working with xenopus oocytes, drosophila, and C. elegans. Not only does she have a wide understanding of model organisms, but Dr. lyer also has had over 10 years of experience in model and assay development and drug screening for human genetic disorders. 

Dr. lyer developed nematode models of rare diseases and conducted several successful screen campaigns for rare diseases, one of which was the aforementioned PMM2, the Phosphomannomutase 2 deficiency. These efforts led to a clinical trial with one patient, Maggie (n=1). The trial outcome was a success! Maggie is doing quite well and the trial is currently being expanded to include other patients. Recently, these findings were published in a paper titled: Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

What is PMM2?

PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a, is a rare multisystem disorder that involves a normal, but complex, chemical process known as glycosylation (PMM2-CDG 2015) 

PMM2-CDG is caused by mutations of the phosphomannomutase-2 (PMM2) gene and is inherited as an autosomal recessive condition. The variation reduces the function of the PMM2 enzyme and leads to improper levels of glycosylation. The disease can affect any part of the body, though most cases usually have an important neurological component. PMM2-CDG is associated with a broad and highly variable range of symptoms and can vary in severity from mild cases to the severe, disabling or life-threatening cases. Most cases appear in infancy or early childhood, like in Maggie’s case, thus, this patient population became the focus of Perlara’s PerlQuest.

Maggie’s Quest

The PMM2 PerlQuest came about because, prior to meeting Maggie, Dr. lyer had started working on lysosomal storage disorders. The research team had just completed some work on a glycosylation disorder (NGLY-1), whose loss of function leads to developmental delay and seizures. In presenting this work, they were introduced to the Maggie’ parents, as PMM2 deficiency is one of the most common causes of glycosylation disorders.  Sangetha and the team at Perlara felt this was a good candidate for using humanizing mutations to create an animal model of the disease in a simple model organism.

“Some model systems work, but not a whole lot and we felt that it fit very well with our platform of model organisms. Perlara was working with yeast model systems, drosophila as well as C. elegans along with the basic model organism pipeline and on the other hand, we had patient fibroblast, which were also available for PMM2. So PMM2 basically came onto our radar because of Maggie, the girl who has PMM2 disorder. And after meeting with her parents and having some conversations about the utility of our platform, we decided to go ahead and model some of our mutations and see if we could conduct a drug screening campaign. That’s how that program came to be.” (Iyer, Podcast: 17 minutes of Science, 2020)

To pursue PMM2 treatment options, Sangeetha and her team at Perlara decided to go down the path of drug repurposing. This involves testing already known drugs and compounds in alternative ways to see if they are viable treatment options for other diseases outside of their initial purpose. One of the main benefits of drug repurposing is that it speeds up the traditional drug discovery timeline as the compounds are already known, and often have vast amounts of information already available for researchers to use. As a result, drug development can be achieved while cutting costs immensely: instead of the typical hundreds of millions it takes to reach clinical trials, drug repurposing trials can be conducted with millions or even sub-millions.

The process:

To begin their repurposing campaign, researchers at Perlara initially started testing with yeast models of PMM2. They then wanted to move into C. elegans, but hit a roadblock. C. elegans already had one PMM2 model, but it was lethal which meant it would not be a viable tool for their campaign. At this point, Perlara approached InVivo Biosystems for help building a new C. elegans model to use. “With InVivo Biosystems’ help, we were able to model another, a different patient mutation, one that does not have this severe lack of enzyme activity”(Iyer, Podcast: 17 minutes of Science, 2020). The new worm model that InVivo Biosystems built for Perlara has an ortholog for PMM2 in which the protein is 54% identical to humans. This may not sound like a lot, but it is very significant. Additionally, and possibly most importantly, the mutation sites were conserved between humans and C. elegans. Because of this conservation, Perlara was able to use the C. elegans models engineered with a specific point mutation that modeled the exact mutation seen in the patient.

“One of the reasons we believed in the power of model organisms specifically for rare monogenic diseases was because when you have a single gene ortholog and one that has high similarity to what one might encounter in humans, you can model the same mutation as you see in humans, in those model organisms.” (Iyer, Podcast: 17 minutes of Science, 2020). 

Dr. lyer performed a drug screen using a 2560-compound Microsource Spectrum library consisting of FDA-approved drugs, bioactive tool compounds and natural products. The top 20 hits were found to be either antidiabetic or antioxidant molecules. Remarkably, the dominant portion of hits were antioxidant flavonoids with known utility as aldose reductase inhibitors (ARIs). Next they checked the activity of the leads in yeast and patient-derived fibroblast to see if cross species conservation of activity can be observed. The result was identification of α-cyano-4-hydroxycinnamic acid (CHCA) as the most cross species bioactive for ARI activity. The structure activity relationship of the CHCA molecule was used to develop a drug pharmacophore profile which allows identification of a set of commercially-available ARIs (tolrestat, ranirestat, imirestat, zopolrestat, sorbinil, ponalrestat, alrestatin, fidarestat and epalrestat).  Testing these new molecules in worms and patient fibroblast revealed epalrestat as the best activity lead.

The aldose reductase is an enzyme that shunts glucose down the polyol pathway with its conversion of glucose into sorbitol. The inhibition of this enzyme activity has two favorable effects. It leads to an increase in glucose-1,6-bisphosphate production which activates PMM2. And it prevent activation of the polyol pathway activity which generates Reactive Oxygen Species (ROS) and leads to Advanced Glycation End-products (“AGE”).  The AGE are especially nasty because they create abnormal protein glycosylation and cause a normal protein to be recognized by the immune system as “foreign” protein. Then a cascade of auto-inflammatory response is initiated.

It is likely PMM2 deficiency set in motion quite a few cellular stress responses. Not only does it result in reduction in normal levels of N-linked glycosylation, it also results in increased shunt of glucose through the polyol pathway. This leads to high levels of sorbitol which readily alkylates with the amines in the body’s proteins rendering the proteins a “foreign” in appearance to the immune system and inflammation results. This ripple effect of cellular stress stress leads to the clinical presentations of the disease. 

“Until the time that we did this work, nobody had discovered that you could boost PMM2 enzyme activity through some other artificial shunt pathway, which is essentially what our model organism screens were telling us, that there was another way to increase PMM2 activity.” (Iyer, Podcast: 17 minutes of Science, 2020).

And while this was true, they had discovered another way to increase PMM2 activity in both their yeast and worm models, they were not certain how this would translate to the human enzyme. At this point, Dr lyer and her team at Perlara were able to incorporate the human fibroblasts which were known to have the defective enzyme activity. The team used both generic Fibroblasts from Coriell, a non-profit repository for patient fibroblasts, in addition to using the fibroblasts from Maggie. In both cases, the fibroblasts showed that PMM2 enzyme activity was in fact increased when exposed to epalrestat. According to Dr lyer, “that’s where the final piece of the puzzle came together.”

Maggie’s Cure

One of the benefits of drug repurposing over developing new compounds is that these drugs are already on the market and have had a wealth of safety data collected. While not always the case, this typically makes it easier to get approval to use the drugs. Although epalrestat had never been approved for use in the US, it had been on the market for over 20 years in other countries and was no longer under patent protection.

At this point, Perlara started talking with Maggie’s family and Dr. Eva Morava from the Mayo Clinic to see about treatment opportunities for Maggie using epalrestat. Dr. Morava, along with Maggie’s parents and Ethan Perlstein, put together an n=1 IND application which they submitted to the FDA in order to gain approval for the use of epalrestat. Thanks to the trove of safety data that was available for epalrestat and the body of data generated by Perlara substantiating that epalrestat increased PMM2 enzyme activity in a variety of modern systems, they were able to gain approval for the trial. 

Maggie has now been on the drug for over a year (Interview conducted when Maggie had been on the drug for about 10 months). She has gained weight and can have conversations, something she was unable to do pre-treatment. Her motor skills and coordination have skyrocketed — she can even ride a bike now. Maggie is continuing to take epalrestat, and her team is now working to expand the trial to a larger group in the hopes of helping others. Dr lyer credits the success of this drug repurposing study to the model organisms which were able to generate the data they needed quickly, efficiently, and affordably in order to gain their FDA approval. 

“To see a drug have an impact, a positive impact, on the child, in a child was just incredibly powerful” (Iyer, Podcast: 17 minutes of Science, 2020)

References

  1. Sangeetha Interview: https://invivobiosystems.com/17-minutes-of-science/from-bench-to-bedside-using-model-organisms-to-find-rare-disease-treatments/?highlight=sangeetha
  2. PMM2-CDG. (2015, August 06). Retrieved April 28, 2021, from https://rarediseases.org/rare-diseases/pmm2-cdg/#:~:text=Summary,chemical%20process%20known%20as%20glycosylation.
  3. Iyer, S., Sam, F. S., DiPrimio, N., Preston, G., Verhejein, J., Murthy, K., . . . Perlstein, E. (2019, November 11). Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Retrieved from: https://journals.biologists.com/dmm/article/12/11/dmm040584/223279/Repurposing-the-aldose-reductase-inhibitor-and
  4. Aldose reductase inhibitors for the treatment of Diabetic polyneuropathy. (n.d.). Retrieved April 28, 2021, from https://www.cochrane.org/CD004572/NEUROMUSC_aldose-reductase-inhibitors-for-the-treatment-of-diabetic-polyneuropathy#:~:text=Aldose%20reductase%20inhibitors%20are%20a,or%20reverse%20progression%20of%20neuropathy
  5. Aldose reductase inhibitors for the treatment of Diabetic polyneuropathy. (n.d.). Retrieved April 28, 2021, from https://www.cochrane.org/CD004572/NEUROMUSC_aldose-reductase-inhibitors-for-the-treatment-of-diabetic-polyneuropathy#:~:text=Aldose%20reductase%20inhibitors%20are%20a,or%20reverse%20progression%20of%20neuropathy

The Good, Bad and the Ugly of Reactive Oxygen Species

Like Clint Eastwood, I have always enjoyed the liberation of doing things a bit different from the standard way, but when it comes to the Free Radicals (peroxides, superoxide, hydroxyl radical, singlet oxygen and alpha-oxygen), one needs to question the intent and effect.

Intriguingly, a little bit of free radical action can extend lifespan (Wang and Hekimi 2015), as demonstrated from C. elegans work where, at under 0.1 mM paraquat, the low levels of superoxide anion lead to longer lifespan (Yang and Hekimi 2010; Yee, Yang, and Hekimi 2014). In fact, these longevity finding led this group to speculate:

“Superoxide generation acts as a signal in young mutant animals to trigger changes of gene expression that prevent or attenuate the effects of subsequent aging.”

Yet it is clear that in C. elegans, when the dose reaches 0.4 mM for paraquat, the animals can no longer reach adulthood (Senchuk, Dues, and Van Raamsdonk 2017). And above this concentration, (at either 2-4 mM chronic exposure for days, or > 20mM acute exposure for a few hours), the effects are lethal to life. So, perhaps a bit like getting exercise, a little bit can do some good, but way too much and it will bring you down. So there appears to be an optimal level of ROS in the cell (“the Good”), where the levels of ROS signalling are good for growth, survival and apoptosis, and yet when ROS is pushed above this low level toxicity to the animal starts to prevail. This helps explain the strange is the “inverted U effect” seen in C. elegans, where antioxidants at low doses may DECREASE lifespan while oxidants at low doses can INCREASE lifespan. Yet at higher doses the effect becomes switched and oxidants compromise lifespan while antioxidant tend to extend it (Desjardins et al. 2017).

In a recent comprehensive review (Shields, Traa, and Van Raamsdonk 2021), this paradox is acknowledged but the general trend is:

“Interventions that increase ROS tend to decrease lifespan, while interventions that decrease ROS tend to increase lifespan.”

Further, this trend provides support for:

“The free radical theory of aging (FRTA), proposes that oxidative damage caused by reactive oxygen species (ROS) is the primary cause of aging.”

Gene Disruption can Manifest as Shorter Lifespan

Progeria (Hutchinson-Gilford Syndrome) is an extremely rare, progressive genetic disorder that causes children to age rapidly, starting in their first two years of life. The LMNA gene is the sole cause of this syndrome, although there are at least a dozen other gene dysfunctions that lead to progeroid syndromes of shortened life (POLR3A, BANF1, WRN, PYCR1, PDGFRB, RECQL2, B4GALT7, SLC25A24, BSCL2, GORAB, ERCC8, ERCC4) or a prematurely-age appearance (LTBP4, FBLN5, ATP6V0A2, ATP6V1A, EFEMP2, ALDH18A1, ELN). Many of these genes are lethal when made as a homozygous KO disruption, but some genes are not essential and can lead to premature aging when removed from the genome in certain organisms. One such gene is DYRK1A. Although the homozygous knockout in mice is lethal (Fotaki et al. 2002), the removal of this gene in C. elegans renders an animal that can survive but have a shortened lifespan.

Specifically, in the loss-of-function KO of the DYRK1A ortholog (mbk-1), the lifespan was found to be about 30% shorter than wild type. When a human coding sequence for DYRK1A was inserted as gene replacement of mbk-1 (hDYRK1A), an intermediate level was achieved for rescue of function. When a clinical variant was installed into the humanized locus (R467Q), a partial loss-of-function defect was observed and one of our clinical partners at the Mayo Clinic, Dr Tom Caulfield, was able to use the assessment to indicate the clinical variant has abnormal DYRK1A function.

Does exposure to antioxidant conditions lead to longer lifespan?

In laboratory studies on genetically-modified model organisms, two generalities prevail. The overexpression of antioxidant enzymes has a tendency to extend lifespan (yeast, flies and worm), while their elimination has a tendency to shorten lifespan (yeast, worms, flies and mice) (Shields, Traa, and Van Raamsdonk 2021). For “chemically-modified” model organisms, these same authors note that a variety of antioxidants (N-Acetyl Cysteine, Vitamin C, and Vitamin E) are known to extend lifespan in some organism (worms, flies and mice), but it remains controversial if there is benefit in humans (Bjelakovic et al. 2012; Bjelakovic, Nikolova, and Gluud 2013).  Even more contradictory, exposure to low levels of ROS generating chemicals (2-deoxy-d-glucose, juglone, paraquat, plumbagin, menadione, rotenone, arsenite, metformin and d-glucosamine) all lead to increased lifespan (yeast, worms, and mice) (Shields, Traa, and Van Raamsdonk 2021).  So in the “chemically-modified” animals due to chemical supplementation, both oxidants and antioxidants can help increase lifespan.  As a result, to get answers for any given compound, a bit of trial and error testing is what is needed (and perhaps a “fist full of dollars”)

Bjelakovic, Goran, Dimitrinka Nikolova, and Christian Gluud. 2013. “Antioxidant Supplements to Prevent Mortality.” JAMA: The Journal of the American Medical Association.

Bjelakovic, Goran, Dimitrinka Nikolova, Lise Lotte Gluud, Rosa G. Simonetti, and Christian Gluud. 2012. “Antioxidant Supplements for Prevention of Mortality in Healthy Participants and Patients with Various Diseases.” Cochrane Database of Systematic Reviews , no. 3 (March): CD007176.

Desjardins, David, Briseida Cacho-Valadez, Ju-Ling Liu, Ying Wang, Callista Yee, Kristine Bernard, Arman Khaki, Lionel Breton, and Siegfried Hekimi. 2017. “Antioxidants Reveal an Inverted U-Shaped Dose-Response Relationship between Reactive Oxygen Species Levels and the Rate of Aging in Caenorhabditis Elegans.” Aging Cell 16 (1): 104–12.

Fotaki, Vassiliki, Mara Dierssen, Soledad Alcántara, Salvador Martínez, Eulàlia Martí, Caty Casas, Joana Visa, Eduardo Soriano, Xavier Estivill, and Maria L. Arbonés. 2002. “Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice.” Molecular and Cellular Biology 22 (18): 6636–47.

Senchuk, Megan M., Dylan J. Dues, and Jeremy M. Van Raamsdonk. 2017. “Measuring Oxidative Stress in : Paraquat and Juglone Sensitivity Assays.” Bio-Protocol 7 (1). https://doi.org/10.21769/BioProtoc.2086.

Shields, Hazel J., Annika Traa, and Jeremy M. Van Raamsdonk. 2021. “Beneficial and Detrimental Effects of Reactive Oxygen Species on Lifespan: A Comprehensive Review of Comparative and Experimental Studies.” Frontiers in Cell and Developmental Biology 9 (February): 628157.

Wang, Ying, and Siegfried Hekimi. 2015. “Mitochondrial Dysfunction and Longevity in Animals: Untangling the Knot.” Science 350 (6265): 1204–7.

Yang, Wen, and Siegfried Hekimi. 2010. “A Mitochondrial Superoxide Signal Triggers Increased Longevity in Caenorhabditis Elegans.” PLoS Biology 8 (12): e1000556.Yee, Callista, Wen Yang, and Siegfried Hekimi. 2014. “The Intrinsic Apoptosis Pathway Mediates the pro-Longevity Response to Mitochondrial ROS in C. Elegans.” Cell 157 (4): 897–909.

Hey People ….its SSSH! time – Getting Easier Integration via Transgenesis Innovation

Contrary to what the librarian says to you when you are part of loud conversation, SSSH! time here is referring to the Self-Selecting Safe Harbor (SSSH) tool invented by Zach Stevenson and crew in the Patrick Phillips Lab at the U of Oregon.

There is a back story here. We are proud of our people at InVivo Biosystems (IVB).  Some, like me, have been hanging around with IVB for quite a long time. Others, like Zach, come and go, but still leave their mark.

Zachary joined us when we were pre-merger Knudra Transgencis.  He was fairly new to genome engineering, but Zach was a quick study.  He became a master of CRISPR-based transgenesis which he leveraged in his next career move – helping him get into graduate school at the University of Oregon.  Zach and the team at Knudra had tasked themselves with the aim of finding better tools for detecting genome integration.  We needed efficient systems that help identify only the animals that have experienced genomic integration. Better yet, the tool would be most effective if only the desired genome integrated strains could survive after exposure to a toxic compound.  During Zach’s time at Kundra, the idea floated around a bit, but it never got the legs of experiment implementation to demonstrate its feasibility.

Once in graduate school Zach teamed up with Megan J. Moerdyk-Schauwecker and Brennen Jamison in the Phillips Lab to get the real world evidence that demonstrated the idea can work.  Their team chose the hygR gene, to determine if a split-hygR gene could be harvested as tool to identify integration in a safe harbor locus (Stevenson et al. G3. 2020)

The principle is simple – chop the hygR gene into two parts.  Put the long part into the genome of C. elegans and put the other part in your transgene plasmid. Zach did this at the MosSCI ttTi5605 safe harbor locus. This transgenic target strain contains most of the hygR gene but is missing a critical segment needed for creation of a functional hygromycin B phosphotransferase. Next, their transgene of interest was made in a plasmid that also contains the missing hygR part. The trick now is to have the same sgRNA site in the plasmid and in the edited safe harbor site. The interaction of the plasmid and the genome when injected with CRISPR reagents renders a region of overlap of about 700 bp on each end of the insertion cargo that allows homology repair to do its magic. When designed right, you only need one sgRNA to initiate the DNA cuts that trigger efficient homologous recombination repair.  This technique works great in C. elegans transgenesis. Add hygromycin B to the growth plates and only the genomic-integrated animals can survive.  Whether it can work in embryo injections with other organisms remains to determined.

At IVB we are building on this to use our fast and easy CRISPR-sdm technique to place a small the small split-hygR fragment at any locus of the genome. This will allow us to drive large constructs 5 to 10 KB (and perhaps even 20-100 KB) into any native locus.

Bottom line: Getting some SSSH! time with this split-hygR technique can calm the frustration of the aggravated C. elegans researcher.

Zebrafish Modeling of SARS-CoV-2 susceptibility in Rare Disease

Five months into the COVID-19 pandemic, the world is at 29,119,433 confirmed cases of SARS-Cov2 infection, including 925,965 deaths (6 August 2020 https://covid19.who.int/), which is over 3% of the planet’s human population. Of all the persons infected with the virus, 3.2% have died. If COVID-19 pandemic follows the trajectory of the 1918 influenza, 1/3rd of the world population will become infected [1], and nearly 300 million deaths will occur in the next few years. To put it in perspective, that is more than twice the number of military and civilian casualties of World Wars I and II combined. The medical community is challenged in optimizing their response due to a highly diverse array of infection severity in the human population. Some individuals are asymptomatic but test positive for SARS-CoV-2 infection, while other exposed individuals experience severe, sometimes fatal COVID-19 infection [2–4]. Disease severity heterogeneity is in part due to patients with underlying health conditions or comorbidities such as hypertension and diabetes which we believe share a common pathophysiology of renin-angiotensin system (RAS) [5]. Estimates for the number of people with an underlying condition for increased severity risk of COVID-19 are 1.7 billion persons (22%) [6]. As a result, there is an urgent need to understand the common molecular and cellular pathophysiologic basis of patients with a diversity of comorbidities and identify those with a rare disease that are at high risk for clinical deterioration. Therefore a rare human disease may be the perfect physiologic model to better understand the disease and generate more individualized therapeutic medical responses and positive outcomes for higher risk COVID-19 groups.

Some Rare Disease groups may be hyper susceptible to COVID-19 infection

There is emerging evidence that RD patients have higher COVID-19 infection risk among all human populations. For example, patients with deficiencies in cellular chloride transport due to CFTR variants associated with Cystic Fibrosis (CF) are more prone to viral and bacterial infection [7]. Yet, because COVID-19 is a newly emergent disease, clear correlation of outcomes in SARS-CoV-2 infection in CF are extremely limited in infected CF patients [8,9] but the concern remains high for these patient groups [10]. Another RD group that is likely to be negatively influenced by SARS-CoV-2 infection, are patents with CADASIL. CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is caused by genetic lesions in the extracellular domain in NOTCH3 [11]. Like CF, CADASIL appears to be linked to accelerated disease progression via Influenza virus infection [12]. Yet the co-morbidity of SARS-CoV-2 infection with NOTCH3 pathogenic variations is only speculated to be associated with advancing CADASIL presentation [13]. Clear evidence is needed in order for a pathological association between COVID-19 infection and CADASIL is supported or refuted. With this knowledge, appropriate therapeutic medical responses can be identified.

The Renin-Angiotensin System (RAS) is at the center for controlling severity of COVID-19 infection.

SARS-CoV-2 utilizes binding of ACE2 to gain entry into host tissues [14]. The resulting internalization and attenuation of ACE2 enzymatic activity is potentially a significant contributor to COVID-19 disease severity. ACE2 is a critical negative regulator of angiotensin activity. Overactive RAS signaling is implicated in higher risk for cardiovascular [15], renal [16,17], and neurodegenerative [18] disease and diabetes [19]. Angiotensin I (Ang I) signaling peptide is produced from the angiotensinogen precursor by the proteolytic activity of renin. In the canonical RAS signaling pathway, Ang I is catalyzed into Ang II by the ACE dipeptidase. Ang II peptide can bind two GPCR receptors AT1R and AT2R with opposing effects. Ang II, a high affinity agonist of the AT1R receptor, promotes inflammation, apoptosis and vasoconstriction, which often results in hypertension of the patient. The agonist activity of Ang II at AT2R receptors has an opposite effect of being anti-inflammatory, anti-apoptotic and vasodilating, which are activities that lead to lower blood pressure. The expression levels of these receptors will have profound influence on hypertension in tissues as well as the presence of Ang II metabolites. Ang II is catalyzed into Ang III by an amino peptidase that remove the N terminal asparagine and results in a molecule with increased affinity for the AT2R receptor and thus activates anti-hypertensive activity [20]. Additional control of the hypertensive state is achieved via the ACE2 dipeptidase which catalyzes Ang I into Ang 1-9 and Ang II into Ang 1-7. Ang 1-9 acts as agonists of the AT2R receptor. Similar to the anti-hypertensive activity of Ang 1-9, the Ang 1-7 peptide also promotes hypotension but through agonist activity on a different GPCR, the MasR receptor [21].

Small Vessel Disease (SVD) is a major health issue.

SVD, defined as “perforating arteries, arterioles, capillaries, and venules” is currently associated with 20% of stroke and 40% of dementia [22]. ACE polymorphisms have been associated with stroke-associated white matter hyperintensities [23] and ischemic stroke [24]. CADASIL is one of the most common single-gene disorders causing cerebral SVD [25]. Hypertension is a risk factor for SVD [26] and leads to vascular remodeling [27]. Since Ang II leads to vascular remodeling via VSMC dedifferentiation [28,29], it becomes plausible that CADASIL variants in NOTCH3 participate in generalizable VSMC remodeling of SVD via altered RAS signaling activity which may predispose these patients to a hypersensitivity to COVID-19 infection. Yet direct evidence is lacking that CADASIL-associated NOTCH3 variants have altered RAS signaling activity that leads to higher viral infectivity and/or RAS stress response.

(adapted from U.S. National Library of Medicine)

The zebrafish animal model is well suited to modeling CVD and CADASIL.

The zebrafish model organism is one of the fastest growing animal models. Walcot and Peterson have proposed zebrafish are a good model for cardiovascular disease due to “its morphological and physiological similarity to human cerebral vasculature, its ability to be genetically manipulated, and its fecundity allowing for large-scale, phenotype-based screens” [30].  For instance a Tg(flk1:GFP) reporter can be expressed in blood vessels and be visualized by fluorescence microscopy. Although iPSCs allow for a more native context, the ability of zebrafish to reproducibly make microvascular structures make them highly attractive for SVD modeling. Further, expertise and skill in gene editing is allowing the rapid creation of gene knock-outs and knock-ins throughout the zebrafish genome. We now have the ability to humanize either by putting in patient gene variations at the zebrafish version of the gene.  Or, swapping out the entire gene for the human gene coding sequence.  The end result is a well controlled system for examining effects of clinical variants on gene function.

CRISPR Engineering can be used to install variants into zebrafish

The creation of precision gene edits in zebrafish allows accurate measurement of the functional consequence of a clinical variant. The use of CRISPR (clustered-regularly-interspaced-short-palindromic-repeats) guide RNA targets cas9 nuclease to a specific genomic locus and has become a common method for targeting DNA cleavage at a genomic locus near a clinical variant target site.  The CRISPR method has become quite routine for genomic locus disruption through Non-Homologous-End-Joining (NHEJ) activity, which creates gene-disrupting indels at a cleaved locus [31,32].  More challenging to achieve is the use of Homology-Directed-Repair to create precision genome editing at a target locus [33]. Often a donor-homology DNA is used to instruct the cell’s natural DNA repair mechanisms to insert a specific sequence of DNA at the cleaved locus. Some groups have developed ways to use donor homology sequences to guide precision insertion of content into the genome of iPSCs and create precision deletions [34] or precision insertion of reporter genes [35,36]. Yet, interference from NHEJ-mediated indels in attempts at precision editing can pose a problem when the researcher desires to  isolate a line with only precision edits. Often biallelic editing occurs in an HDR attempt that results in a complex heterozygote. One allele may report to edit as desired, but often the other sister chromatid locus has an undesirable indel. Development of methods that suppress indel formation by avoiding NHEJ activity can be useful in the creation of a biallelic conversion that creates the desired HDR-mediated edit in both chromatid loci.

A zebrafish model system for assessing COVID-19 viral uptake sensitivity is set up by first humanizing appropriate genes (NOTCH3) and then installing CADASIL-associated variants.

Humanization increases the data relevance of animal models. In this project idea, we can create a humanized zebrafish expressing the hNOTCH3 coding sequence inserted in the first exon of the zebrafish notch3 gene. In a two step procedure, we first use HDR-directed CRISPR gene editing to insert a phiC31 transposase acceptor sequence (attB sequence: CGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTACTCCAC) to disrupt the notch3 locus with early stop codon insertion. Next we rescue the null with phiC31 insertion of hNOTCH3 expression cassette, which is a proven method for inserting large cargo at site specific loci in zebrafish. The cassette cargo contains a self cleaving T2A peptide prior to the human hNOTCH3 coding sequence. This enables expression of the human transgene to be driven by the promoter elements of the zebrafish notch3 gene and yet avoid chimeric protein formation with the vestigial notch3 coding fragment. To create a clinical variant model, the same plasmid used for human hNOTCH3 insertion is modified to contain a clinical variant (C174Y). Heterozygotic animals are expected to be generated (trangene/+). Both the attB containing animal (“knock-out”) and the hNOTCH3(C174Y) are expected to not isolate as homozygous due to essential nature of NOTCH3, while the hNOTCH3(wt) is hoped to remain viable as homozygote. Once these goals and expectations are met, the animals can be used to explore CADASIL associated pathologies. For instance, viral particles expressing the S-peptide receptor binding domain can be exposed to normal and variant zebrafish to monitor for different rates of viral entry.

The uses of a humanized zebrafish model range from diagnostic to drug discovery applications.

Researchers at various institutions can use the animals to determine which human pathologies are conserved. For mechanism-directed drug development, researchers can use in silico methods to discover small molecules that can be screened for specifically restoring the cysteine balance and promoting normal gene function. For pathway-directed drug development, researchers can use the animals for RNA-seq experiment to discover biomarkers consistent with disease and then harvest these genes with high expression response to create fluorescent reporters of pathogenic activity. The end result of this project funding is a platform for rapid assessment and drug discovery in CADASIL-associated disease.

  1. 1918 Pandemic (H1N1 virus). 16 Jun 2020 [cited 28 Aug 2020]. Available: https://www.cdc.gov/flu/pandemic-resources/1918-pandemic-h1n1.html
  2. Paces J, Strizova Z, Smrz D, Cerny J. COVID-19 and the immune system. Physiol Res. 2020;69: 379–388.
  3. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A Systematic Review of Asymptomatic Infections with COVID-19. J Microbiol Immunol Infect. 2020. doi:10.1016/j.jmii.2020.05.001
  4. CDC COVID-19 Response Team. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69: 382–386.
  5. Onweni CL, Zhang YS, Caulfield T, Hopkins CE, Fairweather DL, Freeman WD. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking. Crit Care. 2020;24: 475.
  6. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8: e1003–e1017.
  7. Bucher J, Boelle P-Y, Hubert D, Lebourgeois M, Stremler N, Durieu I, et al. Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy. BMC Infect Dis. 2016;16: 55.
  8. Colombo C, Burgel P-R, Gartner S, van Koningsbruggen-Rietschel S, Naehrlich L, Sermet-Gaudelus I, et al. Impact of COVID-19 on people with cystic fibrosis. Lancet Respir Med. 2020;8: e35–e36.
  9. Cosgriff R, Ahern S, Bell SC, Brownlee K, Burgel P-R, Byrnes C, et al. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. J Cyst Fibros. 2020;19: 355–358.
  10. Manti S, Parisi GF, Papale M, Mulè E, Aloisio D, Rotolo N, et al. Cystic Fibrosis: Fighting Together Against Coronavirus Infection. Front Med. 2020;7: 307.
  11. Wang MM. CADASIL. Handb Clin Neurol. 2018;148: 733–743.
  12. Mizutani K, Sakurai K, Mizuta I, Mizuno T, Yuasa H. Multiple Border-Zone Infarcts Triggered by Influenza A Virus Infection in a Patient With Cerebral Autosomal Dominant Arteriopathy Presenting With Subcortical Infarcts and Leukoencephalopathy. Journal of Stroke and Cerebrovascular Diseases. 2020. p. 104701. doi:10.1016/j.jstrokecerebrovasdis.2020.104701
  13. Williams OH, Mohideen S, Sen A, Martinovic O, Hart J, Brex PA, et al. Multiple internal border zone infarcts in a patient with COVID-19 and CADASIL. Journal of the Neurological Sciences. 2020. p. 116980. doi:10.1016/j.jns.2020.116980
  14. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46: 586–590.
  15. Paz Ocaranza M, Riquelme JA, García L, Jalil JE, Chiong M, Santos RAS, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17: 116–129.
  16. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol. 2004;143: 117–130.
  17. Nishiyama A, Kobori H. Independent regulation of renin-angiotensin-aldosterone system in the kidney. Clin Exp Nephrol. 2018;22: 1231–1239.
  18. Almeida-Santos AF, Kangussu LM, Campagnole-Santos MJ. The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review. Protein Pept Lett. 2017;24: 841–853.
  19. Henriksen EJ, Prasannarong M. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2013;378: 15–22.
  20. Bouley R, Pérodin J, Plante H, Rihakova L, Bernier SG, Maletínská L, et al. N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor. Eur J Pharmacol. 1998;343: 323–331.
  21. Cha SA, Park BM, Kim SH. Angiotensin-(1-9) ameliorates pulmonary arterial hypertension angiotensin type II receptor. Korean J Physiol Pharmacol. 2018;22: 447–456.
  22. Coupland K, Lendahl U, Karlström H. Role of NOTCH3 Mutations in the Cerebral Small Vessel Disease Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Stroke. 2018;49: 2793–2800.
  23. Paternoster L, Chen W, Sudlow CLM. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects. Stroke. 2009;40: 2020–2026.
  24. Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One. 2012;7: e46495.
  25. Choi JC. Genetics of cerebral small vessel disease. J Stroke Cerebrovasc Dis. 2015;17: 7–16.
  26. Cuadrado-Godia E, Dwivedi P, Sharma S, Ois Santiago A, Roquer Gonzalez J, Balcells M, et al. Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke Cerebrovasc Dis. 2018;20: 302–320.
  27. Renna NF, de Las Heras N, Miatello RM. Pathophysiology of vascular remodeling in hypertension. Int J Hypertens. 2013;2013: 808353.
  28. Xu H, Du S, Fang B, Li C, Jia X, Zheng S, et al. VSMC-specific EP4 deletion exacerbates angiotensin II-induced aortic dissection by increasing vascular inflammation and blood pressure. Proc Natl Acad Sci U S A. 2019;116: 8457–8462.
  29. Mondaca-Ruff D, Riquelme JA, Quiroga C, Norambuena-Soto I, Sanhueza-Olivares F, Villar-Fincheira P, et al. Angiotensin II-Regulated Autophagy Is Required for Vascular Smooth Muscle Cell Hypertrophy. Front Pharmacol. 2018;9: 1553.
  30. Walcott BP, Peterson RT. Zebrafish models of cerebrovascular disease. J Cereb Blood Flow Metab. 2014;34: 571–577.
  31. Ma Y, Zhang L, Huang X. Genome modification by CRISPR/Cas9. FEBS J. 2014;281: 5186–5193.
  32. Zhang J-H, Adikaram P, Pandey M, Genis A, Simonds WF. Optimization of genome editing through CRISPR-Cas9 engineering. Bioengineered. 2016;7: 166–174.
  33. Pawelczak KS, Gavande NS, VanderVere-Carozza PS, Turchi JJ. Modulating DNA Repair Pathways to Improve Precision Genome Engineering. ACS Chem Biol. 2018;13: 389–396.
  34. Deneault E, White SH, Rodrigues DC, Ross PJ, Faheem M, Zaslavsky K, et al. Complete Disruption of Autism-Susceptibility Genes by Gene Editing Predominantly Reduces Functional Connectivity of Isogenic Human Neurons. Stem Cell Reports. 2018;11: 1211–1225.
  35. Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146: 318–331.
  36. Deneault E, Faheem M, White SH, Rodrigues DC, Sun S, Wei W, et al. or human iPSC-derived neurons from individuals with autism develop hyperactive neuronal networks. Elife. 2019;8. doi:10.7554/eLife.40092

COVID19 Pandemic: Problems and Solutions – What Can We Do?

Like many responsible citizens of the USA, I am hunkered down in self quarantine.  Trying to come to grips with new uncertainty in the world and how it will have impact on my life.  I find myself wanting to help. To do what I can to help stop this beast we call COVID19. But How?

Collective Behavior Modification is Part of the Answer.

What we are dealing with here mutually is a form of trauma.  We are experiencing the Kuber-Ross grief cycle. Each of us are oscillating somewhere along its spectrum.


image credit: adapted from psycom.net/depression.central.grief

Many of us are stuck in denial.  Although as of late, I seem to be bouncing from anger to bargaining to depression and back again (note, this entire piece for the blog is an elaborate form of bargaining!!!) 

I want to get to acceptance and start doing constructive things.

Shedding the denial by attempting to understand the size of the problem.

If you somehow have been in a timewarp, or you have been tunneling under a rock for the past few months, COVID19 is a raging pandemic that is threatening to kill our parents/grandparents. And it is causing major economic crises throughout the world. Some of our leadership say this will pass in just a few weeks from now, but when you dive into the data, that suggestion is just plain ludicrous fantasy. It will take many months of concerted efforts by everyone to tackle the COVID19 problem. If we choose to ignore what we need to do, the ramifications are immense.

Some are calling it a war, so lets look at it from that lens.

The civil war was an extremely traumatic event for my home country of the USA.  We are still dealing with its baggage to this day and its death toll was immense. World War II was a big effort, industries stopped what they were doing and channeled vast resources to the war effort. Many a dad and mum did not come home, but the concentrated effort of its population probably helped reduce loss of life.  When we look at the loss of life from World War II we have a significant 290 deaths per 100,000. Everyone knew someone who did not come home. Yet, that death rate pales in comparison to what unmitigated COVID19 could do to us in the coming months if unchecked. More than twice as many dead if we do nothing.

Is All This Stuff Real?  – Yes, ….This is Getting Real, …Real Quick

A recent article by a very respected group of researchers paints an alarming picture. Ferguson et al released a study March 16 that describes 3 scenarios each with different consequence on the health system measured in critical care beds occupied per 100,000 population.


image credit: adapted from Ferguson et al.

Scenario 1. Do Nothing. 

In this scenario (black line) we get the 2.2 million dead in the USA. The surge capacity of hospital beds is overwhelmed 25x.  Many die that could have been saved, if we had the resources.

Scenario 2. Mitigation (“soft”)

In the mitigation scenario we have multiple options. We can close schools and universities. This surprisingly does not have much effect (green line). The algorithm takes into account “Household contact rates for student families increase by 50% during closure. Contacts in the community increase by 25% during closure” which offsets gains of social distancing achieved with school closure.  Case isolation by itself has a stronger effect (orange line). For Case Isolation, symptomatic cases are asked to stay home for 7 days. This reduces “non household contacts by 75% for this period. Household contacts remain unchanged. Assumes 70% of households comply with the policy.” Add to Case Isolation a Home Quarantine where family sequesters for 14 days (assume 50% comply), and we get a boost that has more than halved the lethality rate. Finally add in social distancing in the greater than 70 year olds, where this group sequesters themselves away from close contact by avoiding crowd gatherings, maintaining 6 feet distance from strangers, avoiding restaurants and the like, and we get additional decrease in hospitalization (blue line). Yet even this multi-step mitigation effort is not enough. It is too soft to have the needed impact. Even with the multiple mitigation measures in place, the capacity of the health care system is still overwhelmed by more than 8x. More severe and hard measures are needed.

Scenario 3 Suppression (“hard”)

In mitigation, we are creating a decrease in the transmission number (R0 = R “naught”), which is the average number of persons infected by a person who is actively shedding the COVID19 virus.  The do nothing R0 number is 2.4. This means an infectious person spreads COVID19 to an average of 2.4 persons. Mitigation decreases the R0 number, but does not drive it down to 1 or below. To get R0 below 1 where the infected are infecting less than one person, bigger steps need to be taken by the entire population.  To implement effective suppression, we do the Case Isolation, as seen in mitigation, but now we add in General Social Distancing. We ask everyone to avoid getting together in groups exceeding 10 persons. Each of us should maintain 6 foot distance when talking to others. We should capture a sneeze or cough in the elbow or a tissue, and wash hands way more frequently than usual. Further, we should avoid touching our hands to face as much as possible.  It is expected that “all households reduce contact outside the household, school or workplace by 75%. School contact rates are unchanged, workplace contact rates reduced by 25%. Household contact rates are assumed to increase by 25%.” Yet this his is still not enough to get to R0 down to 1, so we explore two more steps as options.

image credit: adapted from Ferguson et al.
  • Option 1. (Case Isolation and General Social Distancing) + Household Quarantine
  • Option 2. (Case Isolation and General Social Distancing) + School and University Closure

We can see that adding in Household Quarantine, during the 5 months that suppression measures are in place, gets us just to the hospital bed surge capacity (red line). Yet in contrast, School and University Closure has an even more pronounced effect.  During the 5 month period, we are well below the stress capacity of the medical services. We will know the success of our suppression approaches when there is no capacity problem being detected.

Herd Immunity – Resisting the Urge to Celebrate Too Soon.

Unfortunately, when the suppression measures are lifted, the COVID19 is due to come roaring back this fall. The advantage of option 1 (Household Quarantine) is it allows for better development of Herd Immunity.  From wikipedia we have the definition of Herd Immunity as occurring “when a large percentage of a population has become immune to an infection, whether through previous infections or vaccination, thereby providing a measure of protection for individuals who are not immune”  With an R0 of 2.4 for COVID19, roughly half of a population needs to be exposed, either by recovering from infection or use of effective vaccine, and R0 is driven down to 1 or less.

Pharmaceutical Interventions – what can we do?

Chloroquine. Currently there are no approved treatments as a vaccine or drug therapy against COVID19. Yet, if we had them in place, we might be able to more quickly get control of this infectious disease and be spared the estimated 12 to 18 months of various mitigation and suppression techniques – approaches that slowly build herd immunity at the least amount of deaths. Scientists and the pharmaceutical industry are rallying quickly get pharmaceutical interventions in place.  And they have made some interesting findings. Hydroxychloroquine, less toxic than Chloroquine, has undergone a small clinical trial on COVID19 patients with very encouraging results. Gautret et al observed a dramatic 2-3 fold faster clearance of SARS-CoV-2 (the “official name” of the COVID19 virus) relative to untreated controls. The results became even more dramatic for another small group of patients that received both hydroxychloroquine and azithromycin – complete clearance in all patients was observed at day 4 of the 6 day observation window.  Yet the numbers tested are tiny. So repeating this in larger populations will tell us if they are onto something. Nevertheless, it is a promising start. The current hypothesis is that this antimalarial drug blocs viral envelope fusion by altering the pH of the endosome and thereby slowing down the activity of the acid proteases present (cathepsins or possibly TMPRSS2).  Yet it is important to consult a doctor first, because self medication has resulted in unnecessary death.

image credit: adapted from PLoS Pathog, 10 (11), e1004502 2014

The action of chloroquine may be multimodal.  In 2005, it was demonstrated chloroquine in a SARS-CoV infection of a cell line caused incomplete glycosylation of ACE2 and that it can have “an antiviral effect during pre- and post-infection conditions suggest that it is likely to have both prophylactic and therapeutic advantages.

Camostat mesilate. In a drug targeting approach, Hoffmann et al monitored the classic endosomal-lysosomal entry for coronaviruses with an endosomal fusion assay. They found entry into the cytoplasm to be mediated by the activity of TMPRSS2 and cathepsin proteases. First, these authors made a comparison between SARS-CoV (the coronavirus causing the pandemic of 2012) and the SARS-CoV-2 (the coronavirus causing the current COVID19 pandemic) and found S protein In COVID19 is more prone to cleavage at the S1/S2 site. Next, they looked at inhibitors of cathepsin (E-64d) and TMPRSS2 (camostat) and found that, depending on cell type, inhibition by either protease could interfere with early fusion. When they looked at a lung cell line (Calu-3), they found that camostat could strongly inhibit early fusion. The site of cleavage for TMPRSS2 protease is the same site for furin and loss of this ability to cleave S-protein is critical for viral entry into the cell. Further Camostat is nearly established for efficacy and safety in humans for treating pancreatitis.  In summary, these researchers found “SARS-CoV-2 can use TMPRSS2 for S protein priming and camostat mesylate, an inhibitor of TMPRSS2, blocks SARS-CoV-2 infection of lung cells.”   So we have two very good candidate molecules for use in suppressing COVID19.

image credit: adapted from Hoffmann 2020

Smoking Gun – But Where is the Expression?

Although camostat can have a dramatic impact on early fusion and it appears to be acting on TMPRSS2 serine protease, what has puzzled me is the tissue specificity. If the primary mode of infection is the lung, then it stands to reason that lung tissue should have high expression of the protease. Yet when one looks at the tissue-specific expression profiles on the Human Protein Atlas (HPA), the expression of TMPRSS2 is absent in the lung.

image credit: https://www.proteinatlas.org/

TMPRSS2 is related to TMPRSS11D 55% sequence similarity and 40% identity). The  Pharos Drug Database indicates the TMPRSS11D gene may also be involved in coronavirus fusion in the cell.  Like TMPRSS2, the Pharos database indicates TMPRSS11D protease “plays a role in the proteolytic processing of ACE2.” Intriguingly, the TMPRSS11D gene has a signature for expression for being in lung tissue via Human Protein Atlas (HPA) (dark green bar). Further, examining ligands for these two genes via the Pharos Drug Database indicates both proteins share two ligands (compound 5 and its derivative CHEMBL1809251). Since these shared molecules have similar binding affinities between the proteins, it may be the  topography of their active sites is similar. Although they both can cleave ACE2, it remains to be shown if they also have similar activities on the S protein. Yet if true, then we have two enzymatic targets for therapeutic development.

image credit: https://www.proteinatlas.org/

ACE2 expression also puzzled me. Its protein expression overview in Human Protein Atlas (HPA) shows no lung expression but expression in the gut is off-the-charts. Auguring in on two papers indicates that its expression does occur in the lung, but only in a small subset of lung cells . These references indicate many other tissues have high expression of of ACE2 (gut and throat). Further examination of tissue localization for SARS-CoV-2 indicates the following tissues exhibit high infection. We have our expected lung (alveolar epithelial cells) but we also have gut (mucosal enterocytes of the intestine, stomach, trachea/bronchus, distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal gland, liver and cerebrum) and many of these tissues also express ACE2.

Using Molecular Dynamics Modeling to Dock Candidate Compounds

image credit: adapted from PyMOL rendering

If an enzyme has a good crystal structure, one can do simulated docking of compounds to come up with categories of interacting molecules that can be used as hits for exploring their capacity to block viral entry into target cells. Regrettably crystal structures are lacking for both TMPRSS2 and TMPRSS11D. Not true for ACE2 gene, since the finding of its association to SARS in 2003, multiple crystal structures are available (6LZG, 6M0J, 6M17, 6VW1). In one recent structure, we can see the binding interface between CoV-2 and ACE2. One approach might be to design an interference molecule that “cloaks” the ACE2 molecule. Ideally, it would interfere with S protein binding but not block normal enzymatic activity. 

image credit: adapted from PyMOL rendering

Another possible target for drug development is the main protease (“Mpro”). The main protease (also called “3CLpro”) is a protease that helps process the long protein polymer made from the viral genome into functional fragments.  The main protease as been derived for its structure at the molecular level. A peptidomimetic α-ketoamides as broad-spectrum inhibitors has been designed and if safety profiling indicates it has low toxicity against human proteases, screening other drug candidates for interaction could prove to be therapeutically useful.

Time is of the essence – the evolving landscape

Finding new therapeutic approaches quickly is important because as COVID19 spreads, the virus is able to explore diversity through mutation. Increasing levels of heterogeneity can be expect for a single stranded RNA virus – errors in the genome during the viral replication cycle will accumulate.  A recent study was made available on the web that looks at genetic diversity among COVID19 strains.  Especially disconcerting is that as the virus spreads, different strains are arising with different mutational lineages.  Mutations in the S-peptide binding to ACE2 or in the S1/S2 cleavage site could render a new lineage that is more virulent.  This is important because the binding affinity (Kd) of SARS-CoV-2 is nearly 5x more than Sars-CoV.


image credit: nextstrain.org/ncov

Fight Viral Diversity with Human Diversity

The natural diversity of human populations might offer some defense against viral evolution.  The Gnomad database is a good resource for examining the diversity in humans. If we look at the binding interface between S-peptide and human ACE2, we cans see if there are humans with variations at the binding interface which may disrupt COVID19 infections. There are multiple EM structures to reference for examining the binding interface (6LZG, 6M0J, 6M17, 6VW1). Using the 6M17 structure, Yan et al showed the binding interface is in close proximity to many residues in ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353, and Arg357).


image credit: Yan et al. Science  04 Mar 2020:

Many gene variants seen in human populations exist at this binding interface. One intriguing residue is Lys26Arg. This genetic variation exist in 600 for every 100,000 persons. Although the change may not seem to be too drastic – a positive charged amino acid is substituted with a similarly charged amino acid.  Yet we know that it is arginine, and according to a prior blog post, the arginine amino acid hold special privilege for its involvement in population variation analysis.

We can float two hypothesis regarding this Lys26Arg variant  

Hypothesis A – Resistance: Persons with the Lys26Arg human variant might have an ACE2 protein with disrupted interaction to the S-protein spike. The S-protein becomes highly compromised for tricking this ACE2 protein into helping it get inside the cell.  


Hypothesis B – Sensitivity: Persons with the Lys26Arg human variant might have an ACE2 protein exhibiting stronger interaction to the S-protein spike. The S-protein can use this ACE2 protein to get inside the cell more efficiently.

The Problem of Heterogeneity

We are diploid organisms which means we have two copies for every gene.  In regards to hypothesis A, this mean most of the persons carrying the Lys26Arg have only one copy.  The other copy is the common natural variant (“wildtype”). Because they harbor a wild type variant, these persons at best would about 50% less susceptible. Thus hypothesis A for COVID19 resistance would be a subtle effect.  If on the other hand, the variant had 10x has more binding to S-protein, then persons carrying this variant could be more susceptible at greater than 2 fold effect. Systems that could measure these binding effects in diploid animal formats would be elucidating for which hypothesis dominates for a given variant.

In summary, there are promising targets for developing therapeutics and vaccines. One target is the interaction of SARS-CoV-2 with ACE2. Another target is the activity of the human proteases (TMPRSS2, cathepsins and possibly TMPRSS11D) that process and cleave the S2 fragment of the spike (S-protein) allowing it to have easier access into the cell. And finally, the third target is the main protease, the enzyme that processes the polypeptide made from the mRNA transcript of the COVID19 genome.